MYGNMyriad Genetics, Inc.

$454M

Q1 2018 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$194M-1.7% YoY

Gross Profit

$149M77.2% margin

Operating Income

$17M8.8% margin

Net Income

$11M5.9% margin

EPS (Diluted)

$0.16

QoQ Revenue Growth

-0.3%

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

$9M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$270M

Stockholders' Equity

$948M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$194M	$197M	-1.7%
Gross Profit	$149M	$153M	-2.1%
Operating Income	$17M	$13M	+31.8%
Net Income	$11M	$4M	+171.4%

Revenue Segments

Diagnostics

$180M93%

All Other Segments

$14M7%

MYGN Q1 2018 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena